Contact this trialFirst, we need to learn more about you.
Proteasome Inhibitor
Daratumumab + VRd for Multiple Myeloma
Recruiting2 awardsPhase 3
Brampton, Ontario
This trial is testing whether adding daratumumab to the standard treatment for multiple myeloma will improve the rate of patients achieving undetectable levels of the disease.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.